Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (81-90 of 436) with videos related to

Pageof 44
Sort By:
The Oncologist|February 16, 2006
Do oncologists believe new cancer drugs offer good value?Eric Nadler, Ben Eckert, Peter J Neumann
JAMA|January 22, 2003
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello, Meredith Rosenthal, Peter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|January 7, 2016
Cost-effectiveness of adherence-enhancing interventions: a systematic reviewTzahit Simon-Tuval, Peter J Neumann, Dan Greenberg
Patient Preference and Adherence|December 27, 2022
Patient and Caregiver Views on Measures of the Value of Health InterventionsDominic Voehler, Peter J Neumann, Daniel A Ollendorf
Health Affairs (Project Hope)|January 14, 2005
When is evidence sufficient?Karl Claxton, Joshua T Cohen, Peter J Neumann
American Journal of Preventive Medicine|December 1, 2012
A role for research: an observation on preventive services for womenNatalia Olchanski, Joshua T Cohen, Peter J Neumann
Health Affairs (Project Hope)|September 6, 2022
State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage PopulationsLauren A Do, Benjamin C Koethe, Allan T Daly, et al.
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D Chambers
Value in Health Regional Issues|April 27, 2018
The State of Cost-Utility Analyses in Asia: A Systematic ReviewTeja Thorat, Pei-Jung Lin, Peter J Neumann
The New England Journal of Medicine|November 12, 2021
Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?Peter J Neumann, Joshua T Cohen, Daniel A Ollendorf
Pageof 44

Showing results (81-90 of 436) with videos related to

Sort By:
Pageof 44
The Oncologist|February 16, 2006
Do oncologists believe new cancer drugs offer good value?Eric Nadler, Ben Eckert, Peter J Neumann
JAMA|January 22, 2003
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello, Meredith Rosenthal, Peter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|January 7, 2016
Cost-effectiveness of adherence-enhancing interventions: a systematic reviewTzahit Simon-Tuval, Peter J Neumann, Dan Greenberg
Patient Preference and Adherence|December 27, 2022
Patient and Caregiver Views on Measures of the Value of Health InterventionsDominic Voehler, Peter J Neumann, Daniel A Ollendorf
Health Affairs (Project Hope)|January 14, 2005
When is evidence sufficient?Karl Claxton, Joshua T Cohen, Peter J Neumann
American Journal of Preventive Medicine|December 1, 2012
A role for research: an observation on preventive services for womenNatalia Olchanski, Joshua T Cohen, Peter J Neumann
Health Affairs (Project Hope)|September 6, 2022
State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage PopulationsLauren A Do, Benjamin C Koethe, Allan T Daly, et al.
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D Chambers
Value in Health Regional Issues|April 27, 2018
The State of Cost-Utility Analyses in Asia: A Systematic ReviewTeja Thorat, Pei-Jung Lin, Peter J Neumann
The New England Journal of Medicine|November 12, 2021
Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?Peter J Neumann, Joshua T Cohen, Daniel A Ollendorf
Pageof 44